Expression of Receptor Activator of Nuclear – Kappa β Ligand in Patients with Metastatic Bone Disease

Rahadyan Magetsari; Ery Kus Dwianingsih; Nicolaas Cyrillus Budhiparama; Irene Araneta; Yudha M. Sakti

doi:10.3889/oamjms.2022.7696

Authors

Rahadyan Magetsari Department of Orthopaedics and Traumatology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; Dr. Sardjito General Hospital, Yogyakarta, Indonesia
Ery Kus Dwianingsih Department of Anatomical Pathology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; Dr. Sardjito General Hospital, Yogyakarta, Indonesia https://orcid.org/0000-0002-0484-7773
Nicolaas Cyrillus Budhiparama Department of Orthopaedics and Traumatology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
Irene Araneta Department of Orthopaedics and Traumatology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; Dr. Sardjito General Hospital, Yogyakarta, Indonesia
Yudha M. Sakti Department of Orthopaedics and Traumatology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; Dr. Sardjito General Hospital, Yogyakarta, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2022.7696

Keywords:

mRNA expression, Receptor activator of nuclearfactor kβ L, Lactate dehydrogenase, Neutrophil-lymphocyte ratio, Bone metastasis

Abstract

BACKGROUND: Bone metastasis is a complication that often occurs due to cancer in solid organs, and more often compared to primary bone tumors. Bone metastasis is associated with excessive osteolytic processes.

AIM: This study was conducted to reveal the correlation between Receptor Activator of Nuclear factor kβ Ligand (RANKL) expression, lactate dehydrogenase (LDH), and neutrophil-lymphocyte ratio (NLR) level in patients with bone metastatic lesions.

METHODS: This cross-sectional study was conducted in 15 subjects with bone metastatic lesions. The specimens were fresh bone tissues obtained by open biopsy. Expression of RANKL in mRNA level was detected quantitatively using reverse transcription-polymerase chain reaction. LDH and NLR were analyzed from the peripheral blood analysis. The correlation of RANKL expression with LDH and NLR was statistically analyzed.

RESULTS: This study enrolled 15 subjects with bone metastasis disease based on the clinical, radiological, and histopathological results. The means of LDH, NLR, and RANKL expression were not significantly different. There was no significant association between the characteristics of metastatic lesion and RANKL expression. The correlation between LDH levels with RANKL expression was positive (p < 0.05), while the correlation between NLR and RANKL expression was negative (p < 0.05).

CONCLUSION: RANKL expression was positively correlated with LDH and negatively correlated with the NLR. Both LDH and NLR can be used as predictive factors of RANKL expression in bone metastasis.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Nayir E. Pathogenesis of bone metastasis. J Oncol Sci. 2016;1:13-6. DOI: https://doi.org/10.1016/j.jons.2015.11.004

Bussard KM, Gay CV, Mastro AM. The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev. 2008;27(1):41-55. https://doi.org/10.1007/s10555-007-9109-4 PMid:18071636 DOI: https://doi.org/10.1007/s10555-007-9109-4

Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55(1):61-6. https://doi.org/10.1038/bjc.1987.13 PMid:3814476 DOI: https://doi.org/10.1038/bjc.1987.13

Mundy GR. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2(8):584-93. https://doi.org/10.1038/nrc867 PMid:12154351 DOI: https://doi.org/10.1038/nrc867

Narayanan P. Denosumab: A comprehensive review. South Asian J Cancer. 2013;2(4):272-7. https://doi.org/10.4103/2278-330X.119895 PMid:24455656 DOI: https://doi.org/10.4103/2278-330X.119895

Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655-64. https://doi.org/10.1056/NEJMra030831 PMid:15084698 DOI: https://doi.org/10.1056/NEJMra030831

Chung PL, Zhou S, Eslami B, Shen L, LeBoff MS, Glowacki J. Effect of age on regulation of human osteoclast differentiation. J Cell Biochem. 2014;115(8):1412-9. https://doi.org/10.1002/jcb.24792 PMid:24700654 DOI: https://doi.org/10.1002/jcb.24792

Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, et al. Bench to bedside: Elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012;11(5):401-19. https://doi.org/10.1038/nrd3705 PMid:22543469 DOI: https://doi.org/10.1038/nrd3705

Huang L, Cheng YY, Chow LT, Zheng MH, Kumta SM. Tumour cells produce receptor activator of NF-κB ligand (RANKL) in skeletal metastases. J Clin Pathol. 2002;55(11):877-8. https://doi.org/10.1136/jcp.55.11.877 PMid:12401833 DOI: https://doi.org/10.1136/jcp.55.11.877

Kitazawa S, Kitazawa R. RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol. 2002;198(2):228-36. https://doi.org/10.1002/path.1199 PMid:12237883 DOI: https://doi.org/10.1002/path.1199

Vano YA, Oudard S, By MA, Têtu P, Thibault C, Aboudagga H, et al. Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or fantasy? A prospective cohort study in metastatic cancer patients. PLoS One. 2018;13(4):e0195042. https://doi.org/10.1371/journal.pone.0195042. PMid:29624591 DOI: https://doi.org/10.1371/journal.pone.0195042

Rove KO, Crawford ED. Metastatic cancer in solid tumors and clinical outcome: Skeletal-related events. Oncology. 2009;23 Suppl 14:21-7. PMid:20128325

Virk MS, Lieberman JR. Tumor metastasis to bone. Arthritis Res Ther. 2007;9 Suppl 1:S5. https://doi.org/10.1186/ar2169 PMid:17634144 DOI: https://doi.org/10.1186/ar2169

Peng X, Guo W, Ren T, Lou Z, Lu X, Zhang S, et al. Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer. PLoS One. 2013;8(3):e58361. https://doi.org/10.1371/journal.pone.0058361 PMid:23516466 DOI: https://doi.org/10.1371/journal.pone.0058361

Whang PG, Schwarz EM, Gamradt SC, Dougall WC, Lieberman JR. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. J Orthop Res. 2005;23(6):1475-83. https://doi.org/10.1016/j.orthres.2005.05.004.1100230634 PMid:16005175 DOI: https://doi.org/10.1016/j.orthres.2005.05.004.1100230634

Cao J, Venton L, Sakata T, Halloran BP. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. J Bone Miner Res. 2003;18(2):270-7. https://doi.org/10.1359/jbmr.2003.18.2.270 PMid:12568404 DOI: https://doi.org/10.1359/jbmr.2003.18.2.270

Roodman GD. Regulation of osteoclast differentiation. Ann NY Acad Sci. 2006;1068(1):100-9. https://doi.org/10.1196/annals.1346.013 PMid:16831910 DOI: https://doi.org/10.1196/annals.1346.013

Conen K, Hagmann R, Hess V, Zippelius A, Rothschild SI. Incidence and predictors of bone metastases (BM) and skeletal-related events (SREs) in small cell lung cancer (SCLC): A Swiss patient cohort. J Cancer. 2016;7(14):2110-6. https://doi.org/10.7150/jca.16211 PMid:27877227 DOI: https://doi.org/10.7150/jca.16211

Katakami N, Kunikane H, Takeda K, Takayama K, Sawa T, Saito H, et al. Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13. J Thorac Oncol. 2014;9(2):231-8. https://doi.org/10.1097/JTO.0000000000000051 PMid:24419421 DOI: https://doi.org/10.1097/JTO.0000000000000051

Ahn H, Lee K, Kim JM, Kwon SH, Lee SH, Lee SY, et al. Accelerated lactate dehydrogenase activity potentiates osteoclastogenesis via NFATc1 signaling. PLoS One. 2016;11(4):e0153886. https://doi.org/10.1371/journal.pone.0153886 PMid:27077737 DOI: https://doi.org/10.1371/journal.pone.0153886

Caliskan B, Korkmaz AN. Can neutrophil/lymphocyte ratio be a predictor for bone metastases of solid tumors? World J Nucl Med. 2016;15(3):196-9. https://doi.org/10.4103/1450-1147.174711 PMid:27651741 DOI: https://doi.org/10.4103/1450-1147.174711

Thio QC, Goudriaan WA, Janssen SJ, Pereira NR, Sciubba DM, Rosovksy RP, et al. Prognostic role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with bone metastases. Br J Cancer. 2018;119(6):737-43. https://doi.org/10.1038/s41416-018-0231-6 PMid:30116026 DOI: https://doi.org/10.1038/s41416-018-0231-6

Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6(1):149-63. https://doi.org/10.2217/fon.09.136 PMid:20021215 DOI: https://doi.org/10.2217/fon.09.136

Huang C, Li S. Association of blood neutrophil lymphocyte ratio in the patients with postmenopausal osteoporosis. Pak J Med Sci. 2016;32(3):762-5. https://doi.org/10.12669/pjms.323.10292 PMid:27375729 DOI: https://doi.org/10.12669/pjms.323.10292

Öztürk ZA, Yesil Y, Kuyumcu ME, Bilici M, Öztürk N, Yeşil NK, et al. Inverse relationship between neutrophil lymphocyte ratio (NLR) and bone mineral density (BMD) in elderly people. Arch Gerontol Geriatr. 2013;57(1):81-5. https://doi.org/10.1016/j.archger.2013.02.005 PMid:23490023 DOI: https://doi.org/10.1016/j.archger.2013.02.005

Ibrahim T, Ricci M, Scarpi E, Bongiovanni A, Ricci R, Riva N, et al. RANKL: A promising circulating marker for bone metastasis response. Oncol Lett. 2016;12(4):2970-5. https://doi.org/10.3892/ol.2016.497 PMid:27698885 DOI: https://doi.org/10.3892/ol.2016.4977